Pioglitazone treatment mitigates cardiovascular bioprosthetic degeneration in a chronic kidney disease model.

ABSTRACT:

Aims

Chronic kidney disease (CKD) is a risk factor for the development of cardiovascular diseases, e.g., atherosclerosis and calcific aortic valve disease, leading inevitably to valve replacement surgery. CKD patients with bioprosthetic cardiovascular grafts, in turn, have a higher risk of premature graft degeneration. Peroxisome proliferator-activated receptor gamma (PPARγ) activation by pioglitazone has cardio-renal protective properties, and research using a heterotopic valve implantation model has shown anti-degenerative effects of PPARγ activation on bioprosthetic valved grafts (BVG) in rats. The present work aims to analyze a potential protective effect of pioglitazone treatment on BVG in an adenine-induced rat model of CKD.

Methods and results

BVG of Sprague Dawley ra

SUBMITTER: Katahira S 

PROVIDER: S-EPMC11338925 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature